CARL vs NPCE: stock comparison and AI forecast
Carlsmed, Inc. (CARL) and Neuropace Inc (NPCE) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CARL Carlsmed, Inc.
- Market Cap
- $410M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
NPCE Neuropace Inc
- Market Cap
- $424M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- CARL and NPCE have similar market capitalizations ($410M and $424M).
- NPCE turns -19.3% of its revenue into net income, against -57.3% for CARL.
- NPCE carries 7.16 times debt per unit of equity, against 0.40 times for CARL.
- Both companies share the SEC industry classification Surgical & Medical Instruments & Apparatus.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CARL | NPCE |
|---|---|---|
| Market Cap | $410M | $424M |
| P/B Ratio | 4.87x | 35.64x |
| EPS | $-1.04 | $-0.58 |
| Book Value/Share | $3.09 | $0.35 |
| Revenue/Share | $2.69 | $2.88 |
| FCF/Share | $-1.27 | $-0.34 |
Profitability & Margins
| Metric | CARL | NPCE |
|---|---|---|
| ROE | -49.9% | -160.8% |
| ROA | -35.6% | -19.7% |
| ROIC | -42.0% | -18.9% |
| Gross Margin | 76.4% | 79.6% |
| Operating Margin | -60.4% | -15.3% |
| Net Margin | -57.3% | -19.3% |
| EBT Margin | -60.4% | -15.3% |
| Tax Rate | 0.0% | 0.0% |
Financial Health
| Metric | CARL | NPCE |
|---|---|---|
| Current Ratio | 8.84x | 4.94x |
| Quick Ratio | 8.66x | 3.91x |
| D/E Ratio | 0.40x | 7.16x |
| Financial Leverage | 1.40x | 8.16x |
| Interest Coverage | -35.3x | -3.7x |
| Working Capital | $97M | $69M |
Cash Flow
| Metric | CARL | NPCE |
|---|---|---|
| Operating Cash Flow | -$34M | -$11M |
| Free Cash Flow | -$35M | -$12M |
| Capital Spending | -$430K | -$370K |
| FCF/Sales | -47.0% | -11.8% |
| CapEx/Sales | 0.6% | 0.4% |
Operational Efficiency
| Metric | CARL | NPCE |
|---|---|---|
| Asset Turnover | 0.62x | 1.02x |
| Receivables Turnover | 5.3x | 6.6x |
| Inventory Turnover | 7.6x | 1.1x |
| Fixed Assets Turnover | 30.6x | 79.5x |
| Days Sales Outstanding | 68 days | 55 days |
| Days Inventory | 48 days | 328 days |
| Payables Period | 78 days | 76 days |
| Cash Conversion Cycle | 38 days | 307 days |
Income Statement
| Metric | CARL | NPCE |
|---|---|---|
| Total Revenue | $73M | $99M |
| Operating Income | -$44M | -$15M |
| Net Income | -$42M | -$19M |
| R&D Expense | $24M | $28M |
| SG&A Expense | $89M | $106M |
| Cost of Goods Sold | $17M | $20M |
Dividend & Shareholder Information
| Metric | CARL | NPCE |
|---|---|---|
| Shares Outstanding | 27M | 34M |
CARL vs NPCE: stock comparison and AI forecast
Which is bigger, CARL or NPCE?
CARL and NPCE have similar market capitalizations ($410M and $424M).
Which one does Intratio's AI model rank higher, CARL or NPCE?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.